drugset
drugset / Trial / NCT07528053

A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants

NCT07528053 ↗

Phase 1 Not yet recruiting 24 enrolled Shanghai Argo Biopharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1 Clinical Study Of BW-20805-2-1001 in Healthy Participants

Timeline

Start
2026-04-28
Primary completion
2026-06-30
Completion
2027-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BW-20805 Unknown — Subcutaneous
Subject BW-20805-2 Unknown — Subcutaneous

Indications

No indication recorded.